Minimal Residual Disease Testing After Induction Chemotherapy for Acute Myeloid Leukemia: Moving Beyond Prognostication?

Walter, Roland B.

doi:10.1200/jco.2018.78.3266

Cited by 4 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with ELN, NCCN, and American Society of Clinical Oncology guidelines, most centers use a combination of methods—including bone marrow morphology, cytogenetics, fluorescence in situ hybridization (FISH), immunophenotyping, and molecular studies—to optimize AML diagnostics and MRD technique sensitivity, specificity, and applicability [ 10 , 13 , 14 , 15 ]. Among these techniques, the most commonly used MRD detection tool is immunophenotyping with multiparameter flow cytometry (MFC) [ 1 , 16 , 17 , 18 , 19 , 20 , 21 , 22 ]. ELN guidelines provide guidance regarding flow cytometry settings, the recommended panel of cell population identifiers, and gating strategy [ 22 ].…”

Section: Mrd Testingmentioning

confidence: 99%

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia

Azenkot

Jonas

2022

Cancers

View full text Add to dashboard Cite

Measurable residual disease (MRD) has emerged as a primary marker of risk severity and prognosis in acute myeloid leukemia (AML). There is, however, ongoing debate about MRD-based surveillance and treatment. A literature review was performed using the PubMed database with the keywords MRD or residual disease in recently published journals. Identified articles describe the prognostic value of pre-transplant MRD and suggest optimal timing and techniques to quantify MRD. Several studies address the implications of MRD on treatment selection and hematopoietic stem cell transplant, including patient candidacy, conditioning regimen, and transplant type. More prospective, randomized studies are needed to guide the application of MRD in the treatment of AML, particularly in transplant.

show abstract

Section: Mrd Testingmentioning

confidence: 99%

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia

Azenkot

Jonas

2022

Cancers

View full text Add to dashboard Cite

show abstract

Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry

Fuda

Chen

2018

Curr Hematol Malig Rep

View full text Add to dashboard Cite

CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones

Houtsma¹,

Meer²,

Meijer

et al. 2022

Blood Advances

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) often presents as an oligoclonal disease whereby multiple genetically distinct subclones can co-exist within patients. Differences in signaling and drug sensitivity of such subclones complicates treatment and warrants tools to identify them and track disease progression. We previously identified over 50 AML-specific plasma membrane (PM) proteins and seven of these (CD82, CD97, FLT3, IL1RAP, TIM3, CD25 and CD123) were implemented in routine diagnostics in patients with AML (n=256) and MDS (n=33). We developed a pipeline termed CombiFlow in which expression data of multiple PM markers is merged, allowing a Principle Component-based analyses to identify distinctive marker expression profiles and to generate single cell tSNE landscapes to longitudinally track clonal evolution. Positivity for one or more of the markers after 2 courses of intensive chemotherapy predicted a shorter relapse-free survival supporting a role of these markers in measurable residual disease (MRD) detection. CombiFlow also allowed the tracking of clonal evolution in paired diagnosis and relapse samples (n=12). Extending the panel to 36 AML-specific markers further refined the CombiFlow pipeline. In conclusion, CombiFlow provides a valuable tool in the diagnosis, MRD detection, clonal tracking, and the understanding of clonal heterogeneity in AML.

show abstract

Minimal Residual Disease Testing After Induction Chemotherapy for Acute Myeloid Leukemia: Moving Beyond Prognostication?

Cited by 4 publications

References 18 publications

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia

Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry

CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones

Contact Info

Product

Resources

About